Journal: The Journal of investigative dermatology

Article Title: Mediators of Capillary-to-Venule Conversion in the Chronic Inflammatory Skin Disease Psoriasis.

doi: 10.1016/j.jid.2022.05.1089

Figure Lengend Snippet: Figure 3. MCAM and its binding partners are specifically upregulated in blood capillaries in psoriasis. (a) Gene expression patterns of MCAM, LAMA4 and KDR in each BEC subtype in healthy and psoriatic conditions. Clusters with significant differences in expression (logFC > 0.2, adjusted P < 0.05) are marked by asterisks. Representative immunofluorescence images showing elevated protein levels of (b) MCAM (green), (e) LAMA4 (green) and (h) KDR (green) in psoriatic (lower) versus in healthy (upper) dermal capillaries stained for CD31 (white) and RGCC (red) as denoted by arrowheads. Bars ¼ 100 mm. Magnified images of the regions of interest (dotted outline) can be found in Supplementary Figure S3. The MFI of (c) MCAM, (f) LAMA4 and (i) KDR in CD31þRGCCþ blood

Article Snippet: Subsequently, the sections were incubated at 4 C overnight with the respective primary antibodies, including mouse antihuman CD31 (1:50, M0823, Dako, Santa Clara, CA), rabbit antihuman RGCC (1:100, HPA063701, Atlas Antibodies, Bromma, Sweden), goat antihuman MCAM (1:50, AF932, R&D System, Minneapolis, MN), sheep antihuman LAMA4 (1:100, AF7340, R&D System), goat antihuman KDR (1:20, AF357, R&D System), rabbit antihuman ERG (1:50, ab92513, Abcam, Cambridge, United Kingdom), mouse antihuman IL-17A (1:50, 14-7179-82, Invitrogen, Waltham, MA), goat antihuman ACKR1 Journal of Investigative Dermatology (2022), Volume 142 (1:100, NB100-2421, Novus Biologicals, Littleton, CO), mouse antihuman VWF (1:50, M0616, Dako), biotin-conjugated goat antihuman LYVE-1 (1:100, BAF2089, R&D System) and mouse antihuman podoplanin (1:100, M3619, Dako).

Techniques: Binding Assay, Gene Expression, Expressing, Staining

Journal: Journal of Translational Medicine

Article Title: Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease

doi: 10.1186/1479-5876-11-219

Figure Lengend Snippet: Detection of ASC surface marker expression by flow cytometry. Mean expression percentage of stem cells markers CD105, CD90, CD73, and CD13, immune stimulation marker HLA-DR, leukocyte marker CD45, endothelial progenitor marker CD34, B-cell marker CD19, monocyte marker CD14, and endothelial markers CD31, CD144, Tie-2, and VEGFR2 (A) . Data is from the first week of stimulation for ASCs in passage three. A representative scatterplot and histograms from one healthy donor (B) for positive (white) and non-positive (grey) populations. The population shown on the scatterplot consists only of viable cells, while the remaining dead cells are gated out with the use of SYTOX dead cell stain. Isotypic controls were used during implementation and proved no unspecific staining. ASCs; Adipose-derived stromal cells, IHD; Ischemic heart disease, CD; cluster of differentiation, HUVEC; human umbilical vein endothelial cell, HLA-DR; Human leukocyte antigen-DR, Tie-2; TEK tyrosine kinase endothelial-2, VEGFR2; vascular endothelial growth factor receptor 2. N = 3 for ASCs and n = 1 for HUVECs. Mean ± SEM.

Article Snippet: Antibodies targeting stem cell markers were CD73 (1:50, polyclonal rabbit anti-human, Abcam, UK) and CD90 (1:100, monoclonal mouse anti-human, Stemgent, MA, US) while those targeting endothelial markers included vWF (ready to use, polyclonal rabbit anti-human, DAKO, Denmark), Tie-2 (1:200, polyclonal rabbit anti-human, Santa Cruz, TX, US), VEGFR2 (1:10, polyclonal goat anti-human, R&D System, UK), CD144 (1:1000, polyclonal rabbit anti-human, Nordic BioSite, Denmark), CD31 (1:100, monoclonal mouse anti-human, DAKO, Denmark), and FOXF1 (1:75, polyclonal rabbit anti-human, Abcam, UK).

Techniques: Marker, Expressing, Flow Cytometry, Staining, Derivative Assay